Sionna CF drug trial fails key endpoint; company halts program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
August 10, 2026 7:00 AM EDTSION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care
Potential confounders in SION-719 Phase 2a trial are being evaluated to inform next steps for the SION-451 dual combination clinical program
Ended Q2 with approximately $268.3 million in cash and plans to take actions to preserve capital while evaluating next steps
Sionna to host conference call today at 8:00 a.m. ET
WALTHAM,... More
